Alexion Pharmaceuticals, Inc.’s Post

Our legacy in #RareDisease is rooted in being the first to translate the complex biology of the complement system, an integral part of the immune system, into transformative medicines. Learn about this powerful tool and how it protects the body against harmful invaders in this video.

Resuming roles in July, the new European Parliament and Commission will have a generational opportunity this year to overcome health inequities for people living with rare diseases, shaping policies that could address the urgent need for faster diagnosis and increased treatment options. Soraya Bekkali, MD, our SVP for EUCAN and International Business reflects on the opportunities and risks of this historic period in the region: http://spr.ly/604195Zil

What is a rare disease? It’s defined as a condition that affects a small population of people, but the definition can vary by region. Swipe to learn how the definition of “rare disease” differs in various countries across the globe. 

It was a privilege to meet with experts at the EAN Congress as we work toward our shared goal of improving patient outcomes for rare neurological diseases.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterised by unpredictable relapses that can lead to long-term disability. Learn why relapse prevention is critical for patients.

Generalised #MyastheniaGravis (gMG) can be challenging to diagnose because its symptoms often mimic other conditions. Continued research and awareness are critical to help patients receive an earlier diagnosis. #MGAwarenessMonth

We're excited to mark a decade of the Congress of the European Academy of Neurology (EAN) at this year’s meeting in Helsinki, Finland. Looking forward to gathering with the medical community to share insights and present our research in gMG and NMOSD, two rare neurological diseases.

This past week was a memorable one for us at Alexion. We welcomed AstraZeneca CEO Pascal Soriot and his Senior Executive Team (SET) to our Boston headquarters for a full itinerary of events and activities. From attending the R&D Science Day where they received exciting updates from across our therapy area teams, to hosting an energising SET Town Hall during which Pascal shared his perspectives on the business and the future of AZ, to visiting a local nonprofit that provides free temporary housing for patients with medical conditions – this week was filled with lively energy, in-person interaction and meaningful connection. And to top it all off, the week concluded with our new 100 Binney Street site dedicated to Genomic Medicine and an exclusive hard-hat tour of 290 Binney St, a future AZ location, both located in Kendall Square. We’re incredibly proud of the tremendous work taking place across the organisation to drive innovation across the Boston life sciences ecosystem and it reinforces the critical role Boston will play in the future of AZ. Check out a recap of this week’s events below.

“It takes a village to bring an AI to real world.” Learn about the AI Diagnostic work Chathuri Daluwatte, PhD leads at Alexion.